stockrowAMNEAL PHARMACEUTICALS, INC.
AMRX Healthcare Drug Manufacturers Specialty & Generic
AMNEAL PHARMACEUTICALS, INC.’s revenue for fiscal 2025 (year ended December 2025) was $3.0 billion, up 8.05% from fiscal 2024.
- Revenue
- +9.96%
- EPS
- +267.0%
- Free cash flow
- −50.9%
- Total debt
- +23.8%
Quarter to September 2026, against a year earlier
Follow AMRX
Alert me
AMNEAL PHARMACEUTICALS, INC. (AMRX) Revenue growth
AMNEAL PHARMACEUTICALS, INC.'s revenue growth over the twelve months to 30 September 2026 was 8.88%, up 0.8 percentage points from fiscal 2025 (8.05%). Over the past ten years it has ranged from −2.20% (fiscal 2019) to 60.9% (fiscal 2018); the current reading is higher than 45% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 5.22% and above the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 8.05% | (8.68) |
| FY2024 | 16.7% | 8.53 |
| FY2023 | 8.20% | 2.53 |
| FY2022 | 5.67% | 0.59 |
| FY2021 | 5.08% | (17.43) |
| FY2020 | 22.5% | 24.71 |
| FY2019 | −2.20% | (63.08) |
| FY2018 | 60.9% | 59.36 |
| FY2017 | 1.52% | (16.81) |
| FY2016 | 18.3% | (26.03) |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Sep 2026 | 9.96% | 0.07 |
| Jun 2026 | 9.89% | 5.99 |
| Mar 2026 | 3.90% | (7.57) |
| Dec 2025 | 11.5% | (0.21) |
| 43 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| LQDA Liquidia Corporation compare | 2,233.7% |
| KNSA Kiniksa Pharmaceuticals International, plc compare | 58.2% |
| HIMS Hims & Hers Health, Inc. compare | 28.0% |
| SUPN Indivior Pharmaceuticals Inc. compare | 16.4% |
| ALKS Alkermes plc compare | 15.3% |
| ELAN Elanco Animal Health Incorporated compare | 12.0% |
| AMRX AMNEAL PHARMACEUTICALS, INC. | 8.88% |
| LNTH Lantheus Holdings, Inc. compare | 2.38% |
| RDY Dr. Reddy's Laboratories Ltd compare | −15.5% |
| Drug Manufacturers Specialty & Generic industry median | 5.22% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on AMRX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement